Gregory P Botta

8PUBLICATIONS
66CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 27, 2026
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Sakti Chakrabarti, Stacey A Cohen, Antony Tin

|Mar 06, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.

Lakshmi Rajdev, Gentry G King, Christopher H Lieu

|Oct 16, 2024
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.

Jonathan Weitz, Daisuke Nishizaki, Joy Liau

|Jul 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.

Gregory P Botta, Maen Abdelrahim, Ronald L Drengler

|Dec 08, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.

Brandon M Huffman, Vasily N Aushev, Griffin L Budde

|Dec 08, 2022
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.

Gregory P Botta, Tridu R Huynh, Samantha R Spierling-Bagsic

Pageof 2

Frequent Collaborators

3 joint publications

Farshid Dayyani

2 joint publications

Meenakshi Malhotra

2 joint publications

Vasily N Aushev

2 joint publications

Pashtoon Murtaza Kasi